Susan Goodin

4.3k total citations
99 papers, 3.4k citations indexed

About

Susan Goodin is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Susan Goodin has authored 99 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 31 papers in Molecular Biology and 24 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Susan Goodin's work include Cancer Treatment and Pharmacology (22 papers), Prostate Cancer Treatment and Research (15 papers) and Cancer, Lipids, and Metabolism (14 papers). Susan Goodin is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Prostate Cancer Treatment and Research (15 papers) and Cancer, Lipids, and Metabolism (14 papers). Susan Goodin collaborates with scholars based in United States, China and Switzerland. Susan Goodin's co-authors include Pascual Medina, Robert S. DiPaola, Eric H. Rubin, Michael P. Kane, Mark N. Stein, Regina S. Cunningham, Xi Zheng, William N. Hait, Peter R. Blower and Matti Aapro and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Susan Goodin

98 papers receiving 3.3k citations

Peers

Susan Goodin

ONCOL

PRM

SURGE

Michael Lind United Kingdom

Brian Booth United States

R. Donald Harvey United States

Lionel D. Lewis United States

Antonello Di Paolo Italy

Angélo Paci France

Benoı̂t Blanchet France

D. Ferry United Kingdom

Jürgen Venitz United States

Gareth J. Veal United Kingdom

Michael Lind United Kingdom

Susan Goodin

1.3k ×1.0

ONCOL

1.3k ×1.1

689 ×1.1

PRM

400 ×0.8

190 ×0.7

SURGE

Citations per year, relative to Susan Goodin Susan Goodin (= 1×) peers Michael Lind

Countries citing papers authored by Susan Goodin

Since Specialization

Citations

This map shows the geographic impact of Susan Goodin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Goodin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Goodin more than expected).

Fields of papers citing papers by Susan Goodin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Goodin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Goodin. The network helps show where Susan Goodin may publish in the future.

Co-authorship network of co-authors of Susan Goodin

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Goodin. A scholar is included among the top collaborators of Susan Goodin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Goodin. Susan Goodin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Spencer, Kristen, Joseph Aisner, Mark N. Stein, et al.. (2023). A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850. Oncotarget. 14(1). 302–315. 5 indexed citations

Xu, Yao, Zhiwei Zhong, Yiwen Gao, et al.. (2021). The Mangrove-Derived Diterpenoid Diaporthe B Inhibits the Stemness and Increases the Efficacy of Docetaxel in Prostate Cancer PC-3 Cells. Natural Product Communications. 16(12).

Ren, Xiangshan, Xiao Wang, Xue-Tao Xu, et al.. (2021). Nobiletin Inhibits Cell Growth, Migration and Invasion, and Enhances the Anti-Cancer Effect of Gemcitabine on Pancreatic Cancer Cells. Natural Product Communications. 16(4). 2 indexed citations

Ren, Xiangshan, Xue-Tao Xu, Panpan Wu, et al.. (2020). Nobiletin, a citrus polymethoxyflavone, enhances the effects of bicalutamide on prostate cancer cellsviadown regulation of NF-κB, STAT3, and ERK activation. RSC Advances. 10(17). 10254–10262. 19 indexed citations

Li, Dongli, Wenfeng Liu, Xiangshan Ren, et al.. (2020). Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures. International Journal of Medical Sciences. 17(12). 1795–1802. 5 indexed citations

Wu, Panpan, Xiao Wang, Xue-Tao Xu, et al.. (2020). (3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells. Bioorganic Chemistry. 101. 104022–104022. 3 indexed citations

Huang, Huarong, Yan He, Lanyue Zhang, et al.. (2018). Phenethyl isothiocyanate in combination with dibenzoylmethane inhibits the androgen-independent growth of prostate cancer cells. Food & Function. 9(4). 2398–2408. 11 indexed citations

He, Yan, Huarong Huang, Dongli Li, et al.. (2017). Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells. Oncology Reports. 37(2). 953–960. 29 indexed citations

Huang, Huarong, Ting Liu, Lin Yu, et al.. (2017). Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures. Bioorganic & Medicinal Chemistry Letters. 27(11). 2286–2291. 12 indexed citations

10.

Richie, John P., Arun K. Das, Ana Calcagnotto, et al.. (2014). Comparative Effects of Two Different Forms of Selenium on Oxidative Stress Biomarkers in Healthy Men: A Randomized Clinical Trial. Cancer Prevention Research. 7(8). 796–804. 36 indexed citations

11.

Wang, Huaqian, Xiaoxing Cui, Susan Goodin, et al.. (2013). Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib. Oncology Reports. 31(2). 835–841. 15 indexed citations

12.

Griffith, Niesha, et al.. (2011). Safe handling of oral chemotherapeutic agents: A European perspective. 5(2). 4–10. 3 indexed citations

13.

Toppmeyer, Deborah & Susan Goodin. (2010). Ixabepilone, a New Treatment Option for Metastatic Breast Cancer. American Journal of Clinical Oncology. 33(5). 516–521. 10 indexed citations

14.

Wong, Serena & Susan Goodin. (2009). Overcoming Drug Resistance in Patients with Metastatic Breast Cancer. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 29(8). 954–965. 48 indexed citations

15.

Goodin, Susan, Kamakshi V. Rao, Michael D. Kane, et al.. (2005). A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer. Cancer Chemotherapy and Pharmacology. 56(2). 199–204. 14 indexed citations

16.

Rao, Kamakshi V., Susan Goodin, Nisha Davé, et al.. (2004). A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. The Prostate. 62(2). 115–122. 51 indexed citations

17.

Doyle-Lindrud, Susan, Sue R. Beers, Susan Goodin, et al.. (2003). A phase I trial of weekly paclitaxel, 13- cis -retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies. Cancer Chemotherapy and Pharmacology. 52(2). 119–124. 21 indexed citations

18.

Chen, Tianling, James R. Berenson, Robert Vescio, et al.. (2002). Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases. The Journal of Clinical Pharmacology. 42(11). 1228–1236. 310 indexed citations

19.

DiPaola, Robert S., Weichung Joe Shih, Yong Lin, et al.. (2001). Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma. Cancer. 92(8). 2065–2071. 18 indexed citations

20.

Goodin, Susan, et al.. (1997). Chemotherapy for Metastatic Melanoma during Pregnancy. Gynecologic Oncology. 66(3). 526–530. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact